TCGA-39-5037-01A-01R-1443-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.530
- MYC_TARGETS_V2+0.530
- MYC_TARGETS_V1+0.520
- OXIDATIVE_PHOSPHORYLATION+0.460
- G2M_CHECKPOINT+0.410
- PANCREAS_BETA_CELLS+0.380
- MTORC1_SIGNALING+0.340
- DNA_REPAIR+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.280
- SPERMATOGENESIS+0.260
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.580
- ANGIOGENESIS-0.500
- INTERFERON_GAMMA_RESPONSE-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.480
- ALLOGRAFT_REJECTION-0.460
- INFLAMMATORY_RESPONSE-0.450
- IL6_JAK_STAT3_SIGNALING-0.430
- COMPLEMENT-0.400
- UV_RESPONSE_DN-0.380
- KRAS_SIGNALING_UP-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BB-8601-01A-11R-2403-07 | — | — | 0.924 |
| 2 | TCGA-33-4532-01A-01R-1201-07 | — | cohortSQ2 | 0.909 |
| 3 | TCGA-33-AAS8-01A-11R-A405-07 | — | cohortSQ2 | 0.900 |
| 4 | TCGA-33-4582-01A-01R-1443-07 | — | cohortSQ2 | 0.900 |
| 5 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.899 |
| 6 | TCGA-22-5491-01A-01R-1635-07 | — | cohortSQ2 | 0.897 |
| 7 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.893 |
| 8 | TCGA-85-8354-01A-31R-2326-07 | — | cohortSQ2 | 0.892 |
| 9 | SRR975602 | — | — | 0.891 |
| 10 | TCGA-64-1678-01A-01R-0946-07 | — | cohortA3 | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.530 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.520 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.460 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.380 | Cobimetinib | — uncovered |
| MTORC1_SIGNALING | 0.340 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.300 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.280 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.220 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.210 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.170 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| PEROXISOME | 0.140 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.100 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.020 | Inavolisib | — uncovered |